MedPath

Tagged News

Bexorg Partners with Biohaven to Advance CNS Drug Development Using AI-Driven Whole-Brain Discovery Platform

AI
  • Bexorg announced a multi-program research collaboration with Biohaven to identify and advance next-generation therapies for central nervous system disorders using its novel whole-brain discovery platform.
  • The platform represents the only technology capable of perfusing isolated human and pig brains with artificial blood to restore metabolic activity for prolonged periods, enabling unprecedented preclinical testing.
  • Bexorg's technology will support two preclinical development programs at Biohaven by demonstrating target engagement and generating biomarkers, pharmacokinetic data, and mechanistic insights.
  • The collaboration aims to overcome traditional translational gaps in CNS drug discovery by providing detailed insights into pharmacology and efficacy before advancing to clinical trials.

AIML Innovations Secures Provisional Patents for AI-Powered ECG Signal Processing Technology

AI
  • AI/ML Innovations Inc. has filed comprehensive provisional patent applications with the USPTO through its subsidiary Neural Cloud Solutions, covering advanced neural network architectures and cloud-based ECG signal optimization workflows.
  • The patent filings protect key innovations within AIML's proprietary AI signal-processing platforms MaxYield™ and CardioYield™, including a dynamic ECG reporting engine that supports clinical workflows with customizable components.
  • These patents strengthen AIML's position in AI-assisted cardiology by protecting both algorithmic foundations and deployment infrastructure, supporting the company's global commercialization strategy.
  • The company maintains a growing regulatory portfolio including a 510(k) premarket notification and registered FDA Device Master File, demonstrating commitment to rigorous validation and broad interoperability.

32 Biosciences Secures $6 Million Funding to Advance Gut Microbiome Diagnostic and Therapeutic Platform

AI
  • 32 Biosciences raised $6 million in funding to advance its AI-powered gut microbiome diagnostic platform and first-of-its-kind non-antibiotic antimicrobial therapy.
  • The company's diagnostic tool uses mass spectrometry and machine learning to quantitatively assess gut microbiome functional health and is targeted for FDA clearance by late 2026.
  • Their therapeutic candidate represents a novel approach to preventing gut-derived bacterial infections without contributing to antibiotic resistance, having shown effectiveness in animal models.
  • The funding will support clinical validation, regulatory submissions, and commercial readiness as the company prepares for Series A fundraising and Phase I clinical trials.

Evogene Completes First-in-Class AI Foundation Model for Small Molecule Design with 90% Precision

AIDrug Discovery
  • Evogene Ltd. has completed its generative AI foundation model version 1.0 for small molecule design, developed in collaboration with Google Cloud, achieving approximately 90% precision compared to 29% in traditional GPT AI models.
  • The model addresses the core challenge of identifying novel small molecules that simultaneously meet multiple complex product criteria while being patentable, essential for both pharmaceutical and agriculture applications.
  • Built on a dataset of approximately 38 billion molecular structures and trained using Google Cloud's advanced AI infrastructure, the model expands ChemPass AI capabilities to generate truly novel molecular structures.
  • Development is already underway on version 2.0 with enhanced flexibility for multi-parameter optimization, incorporating customized parameters tailored to therapeutic contexts and specific agriculture requirements.

Silicogenix Partners with BioDuro to Accelerate AI-Driven Drug Discovery for Complex Diseases

AIDrug DiscoveryOncology
  • Silicogenix, a pioneer in AI-powered small molecule design technology, has formed a strategic partnership with global CRDMO BioDuro to streamline drug discovery for complex and rare diseases.
  • The collaboration combines SGX's proprietary polypharmacology frameworks with BioDuro's integrated drug discovery platform to reduce development costs and timelines from concept to preclinical stages.
  • SGX's technology enables access to the majority of the human proteome and supports novel therapeutic approaches including combination therapies with standard-of-care treatments.
  • The partnership aims to accelerate development of first-in-class oncology and immunology therapeutics that address significant unmet medical needs in complex disease areas.

hellocare.ai Partners with Mayo Clinic to Develop Ambient Clinical Intelligence Technology

AI
  • hellocare.ai has entered into a collaboration with Mayo Clinic to develop ambient clinical intelligence technology that could enable more proactive healthcare approaches and potentially reduce hospitalizations.
  • Mayo Clinic has joined hellocare.ai's $47 million growth round as an investor, expanding the funding for the AI-assisted virtual care platform company.
  • The partnership aims to create next-generation capabilities for early disease detection, reduced clinician workload, and safer inpatient care through AI technology.
  • hellocare.ai's platform is currently deployed across more than 70 health systems, offering services including ambient documentation, digital whiteboards, and hospital-at-home programs.

RenaissThera Advances AI-Designed Oral Obesity Drug Targeting GIPR to Lead Optimization

AIDrug Discovery
  • RenaissThera achieved a major discovery milestone in developing oral small molecule drugs targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR) for obesity treatment.
  • The company's AI and machine learning platforms successfully designed and screened novel GIPR modulators that demonstrated in-vitro and in-vivo activity in mice.
  • These oral small molecules offer a more affordable and convenient alternative to existing peptide-based obesity therapies in a market projected to reach $38 billion by 2032.
  • RenaissThera is now advancing these "hits" to lead optimization and plans to push candidates toward IND-readiness next year.

Alexion Partners with Pangaea Data to Develop AI System for Hypophosphatasia Detection

AIRare Disease
  • Alexion, AstraZeneca's rare disease division, has entered a collaboration with AI platform provider Pangaea Data to develop an artificial intelligence clinical decision support system for detecting hypophosphatasia in adults.
  • The AI system will analyze electronic health records to improve detection of hypophosphatasia, a rare inherited disorder affecting bone mineralization that often remains undiagnosed due to diverse and non-specific symptoms.
  • Hypophosphatasia affects approximately one in 100,000 people in the general population, with patients typically waiting years for accurate diagnosis due to the condition's complex nature and variable clinical presentation.
  • Pangaea Data's AI platform has previously been configured to detect 42 other hard-to-diagnose conditions and will be reconfigured specifically for hypophosphatasia detection through this Alexion-funded partnership.

First Ascent Biomedical Partners with Fight Colorectal Cancer for $350,000 Precision Medicine Study

Precision MedicineAI
  • First Ascent Biomedical and Fight Colorectal Cancer have launched a $350,000 prospective feasibility study to advance precision oncology for colorectal cancer patients using xDRIVE tumor profiling technology.
  • The study will enroll 25 patients with metastatic colorectal cancer in Minnesota, integrating functional drug testing, genetic analysis, and artificial intelligence to provide personalized treatment insights.
  • Led by gastrointestinal cancer specialist Dr. Hao Xie and principal investigator Dr. Noah Berlow, the study aims to complete enrollment within nine months and deliver actionable data to oncologists.
  • The collaboration represents a strategic focus on enhancing care for patients with limited treatment options through advanced research and rapid, individualized tumor profiling.

AI Integration and Advanced Drug Delivery Systems Reshape Pharmaceutical Outsourcing Models

AI
  • Recent developments in drug delivery methods and artificial intelligence advancements are influencing the dynamics of outsourcing models within the pharmaceutical industry.
  • Emerging trends in drug delivery systems have prompted companies to reevaluate their approaches to outsourcing with a focus on innovation and efficiency.
  • AI is playing an increasingly significant role by streamlining processes and enhancing decision-making capabilities in pharmaceutical partnerships.
  • Novel partnership models are emerging that reflect changing market demands and operational strategies as companies adapt to innovation-driven opportunities.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.